PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278789ArticlesСтатьиNONALCOHOLIC STEATOHEPATITIS: DIAGNOSIS AND TREATMENT BASED ON RISK FACTORSНЕАЛКОГОЛЬНЫЙ СТЕАТОГЕПАТИТ: ДИАГНОСТИКА И ЛЕЧЕНИЕ, ОСНОВАННЫЕ НА ФАКТОРАХ РИСКАSeverovaMariya MikhaylovnaСевероваМария Михайловна

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

LopatkinaTat'yana NikolaevnaЛопаткинаТатьяна Николаевна

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

RusskikhAleksandr VadimovichРусскихАлександр Вадимович

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

FominViktor ViktorovichФоминВиктор Викторович

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва

SeverovaM MLopatkinaT NFominV VГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России, Москва20012011182NO2 (2011)№2 (2011)505623022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278789

The article discusses diagnosis strategy and treatment of nonalcoholic fatty liver disease (NAFLD). It is emphasized that the identification of NAFLD based on the detection of relevant risk factors is always associated with high risk of cardiovascular and renal complications. Treatment of NAFLD involves an aggressive effect on the risk factors such as abdominal obesity and disorders of lipoprotein metabolism, particularly hypertriglyceridemia and insulin resistance. Possibility of application of statins, metformin, ursodeoxycholic acid, and other drugs in NAFLD is considered.

Обсуждаются стратегия диагностики и лечения неалкогольной жировой болезни печени (НАЖБП). Подчеркивается, что выявление НАЖБП, во многом строящееся на обнаружении соответствующих факторов риска, всегда означает, что пациент характеризуется очень высоким риском сердечно-сосудистых и почечных осложнений. Лечение НАЖБП подразумевает агрессивное воздействие на факторы риска - наряду с абдоминальным ожирением, к ним относятся нарушения обмена липопротеидов, в частности, гипертриглицеридемия, и особенно инсулинорезистентность. Рассматриваются возможности применения при НАЖБП статинов, метформина, урсодеоксихолевой кислоты и других препаратов.

non-alcoholic steatohepatitisrisk factorsmetabolic syndromeinsulin resistanceobesityhypertriglyceridemiaнеалкогольный стеатогепатитфакторы рискаметаболический синдроминсулинорезистентностьожирениегипертриглицеридемияKirovski G, Schaecherer D, Wobser H, et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with athropometric, biochemical and sonographic characteristics. Int J Clin Exp Med 2010;3(3):202-10.Radu C, Grigorescu M, Crisan D, et al. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J. Gastrointestin. Liver Dis 2008;17(3):255-60.Leite NC, Salles GF, Araujo AL, et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29(1):113-19.Lee JY, Kim KM, Lee SG, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007;47(2):239-44.Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999;94:2467-74.Kleiner DE, Brunt EM, Van Natta ML, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histologic scoring system for NAFLD. Hepatology 2005;41:1313-21.Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122(6):1649-57.Friis-Liby I, Aldenborg F, Jerlstad P, et al. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2004;39(9):864-69.Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21(1):138-43.Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26(7):856-63.Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22(9):1141-45.Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, et al. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009;29(2):159-63.Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int 2009;29(9):1431-38.Verhulst SL, Jacobs S, Aerts L, et al. Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? Sleep Breath 2009;13(2):207-10.Polotsky VY, Patil SP, Savransky V, et al. Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 2009;179(3):228-34.Mishra P, Nugent C, Afendy A, et al. Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int 2008;28(8):1080-86.Kallwitz ER, Herdegen J, Madura J, et al. Liver enzymes and histology in obese patients with obstructive sleep apnea. J Clin Gastroenterol 2007;41(10):918-21.Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007;293(4):871-77.Piro S, Spadaro L, Russello M, et al. Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis 2008;18(8):545-52.Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, et al. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol 2007;13(26):3614-18.Comert B, Mas MR, Erdem H, et al. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 2001;33(4):353-58.Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004;53(10):2623-32.Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007;22(9):1482-89.Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51(2):595-602.Arslan U, Türkoglu S, Balcioglu S, et al. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007;18(6):433-36.Targher G, Bertolini L, Padovani R, et al. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23(4):403-09.Yasui K, Sumida Y, Mori Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2010. [Epub ahead of print].Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 2008;57(4):569-76.Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 2008;19(8):1564-70.Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 2006;40(10):949-55.Salvi P, Ruffini R, Agnoletti D, et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010;28(8):1699-707.Kim HC, Kim DJ, Huh KB. Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis 2009;204(2):521-25.Wang CC, Lin SK, Tseng YF, et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol 2009;24(8):1411-16.Лазебник Л.Б., Звенигородская Л.А., Егорова Е.Г. Метаболический синдром у пациентов с заболеваниями органов пищеварения // Тер. арх. 2007. № 79 (10). C. 9-13.Федоров И.Г., Никитин И.Г., Сторожаков Г.И. Неалкогольный стеатогепатит: клиника, патогенез, диагностика, лечение // Consilium medicum 2004. № 6(6). C. 401-405.Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003;37(5):1202-19.Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12(3):189-92.Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2010;2(4):139-42.Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376(9756):1916-22.Abel T, Feher J, Dinya E, et al. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit 2009;15(12):MS6-MS11.Kondo K, Sugioka T, Tsukada K, et al. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Adv Exp Med Biol 2010;662:77-82.Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2010;95(6):2727-35.Grattagliano I, Portincasa P, Palmieri VO, et al. Managing nonalcoholic fatty liver disease. Recommendations for family physicians. Can Fam Physician 2007;53:853-67.Duseja A, Das A, Dhiman RK, et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007;6(4):222-26.Tock L, Damaso AR, de Piano A, et al. Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents. J Obes 2010:831901.Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 2009;46(2):113-18.Nadeau KJ, Ehlers LB, Zeitler PS, et al. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes 2009;10(1):5-13.Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100(5):1082-90.Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, et al. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol 2004;3(3):108-12.